Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn CofiledCriticalUpjohn Co
Priority to KR7803117ApriorityCriticalpatent/KR790000589B1/en
Application grantedgrantedCritical
Publication of KR790000589B1publicationCriticalpatent/KR790000589B1/en
Title compd. (I), possessing anti-inflammatory activity, was prepd. from 6&, 9&-difluoro-11β, 17, 21-trihydroxy-16β-methylpregna-1,4-diene-3, 20-dione(II) in 3 steps. Thus, II was converted to compd. (III) and then to 6&, 9&-difluoro-11β, 17, 21-trihydroxy-16β-methylpregna-1,4-diene-3, 20-dione-17-acetate (IV). Intermediate IV was 21-acetylated by treating with anhydrous acetate in the presence of a base to give I.
KR7803117A1978-10-141978-10-14Method for producing 6l-fluoro-17,21-dehydroxy-16b-methylpregna-4,9(11)diene-3,20-dione17,21-diacetate
KR790000589B1
(en)
Process for preparing pharmaceuticals comprising 9alpha, 11beta-dichlor-16alpha-methyl-21-(dicyclohexylmethyloxy-carbonyloxy)-pregno-1,4-dien-3,20-dione